MCM
SION

MAI Capital Management’s Sionna Therapeutics SION Stock Holding History

MAI Capital Management’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$81 – 4973
2026
Q1 		$81 Buy
+2
New +$76 ﹤0.01% 4796

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

MAI Capital Management's SION Position: Q2 2026 in Review

MAI Capital Management sold out of Sionna Therapeutics (SION) in Q2 2026, closing a stake of 2 shares — an estimated $81 sold.

MAI Capital Management first reported a position in SION in Q1 2026 and held it in 1 quarter. The position peaked at $81 in Q1 2026. 146 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • MAI Capital Management reported no remaining Sionna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 2 Sionna Therapeutics shares in Q2 2026, an estimated $81.
  • MAI Capital Management first reported a position in Sionna Therapeutics in Q1 2026 and held it in 1 quarter.
  • MAI Capital Management's Sionna Therapeutics position peaked at $81 in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.